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Introduction: The effect of using a borderline zone for the interpretation of the interferon-γ release assay (IGRA) on
the prediction of progression to active tuberculosis (TB) in healthcare workers (HCW) is analysed.
Methods: Data from a published study on TB screening in Portuguese HCW is reanalysed using a borderline zone
for the interpretation of the IGRA. Testing was performed with the QuantiFERON-TB Gold In-Tube (QFT). The
borderline zone for the QFT was defined as interferon (INF) in QFT ≥0.2 to <0.7 IU/mL. An X-ray was performed
when the IGRA was positive (≥0.35 IU/mL) or typical symptoms were present. Sputum analysis was performed
according to the X-ray or the presence of typical symptoms.
Results: The cohort comprised 2,884 HCW with a QFT that could be interpreted. In 1,780 (61.7%) HCW, the QFT
was <0.2 IU/mL. A borderline result was found in 341 (11.8%) and a QFT >0.7 IU/mL in 763 (26.3%) HCW. Fifty-seven
HCW had a TB in their medical history, eight had a TB at the time of screening and progression to active TB was
observed in four HCW. Two out of eight HCW (25%) with active TB at the time of screening had a QFT result falling
into the borderline zone. One out of four HCW (25%) who progressed towards active TB after being tested with
QFT had QFT results falling into the borderline zone. A second IGRA was performed in 1,199 HCW. In total, 292
(24.4%) HCW had at least one of the two IGRA results pertaining to the borderline zone.
Conclusion: Using a borderline zone for the QFT from 0.2 to 0.7 IU/mL should be administered with care, as active
TB as well as progression to active TB might be overlooked. Therefore, the borderline zone should be restricted to
populations with a low TB risk only.
Keywords: Interferon-γ release assay, Tuberculosis, Healthcare workersIntroduction
Screening healthcare workers (HCW) for latent tubercu-
losis infection (LTBI) and active tuberculosis (TB) is funda-
mental in infection control programmes in hospitals [1].
Meanwhile, the interferon-γ release assay (IGRA) is widely
used for TB screening in HCW [2-10]. Nevertheless, some
questions concerning the interpretation of the results of the* Correspondence: a.nienhaus@uke.de
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distribution, and reproduction in any mediumIGRA remain unanswered. This is particularly true for the
interpretation of the IGRA in the serial testing of HCW.
Three reviews have covered the topic of IGRA variabi-
lity in the serial testing of HCW so far [11-13]. All three
came to the conclusion that the reversion of positive
IGRA results to negative results occurs more often than
conversion from negative to positive IGRA results. And
more importantly, the probability of conversion or rever-
sion depends on the quantitative results of the first
IGRA. Therefore, a borderline zone might be helpful in
order to separate real conversions and reversions in
IGRA from variation caused by chance.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,













Figure 1 Flow chart of study population.
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http://www.occup-med.com/content/8/1/1Two IGRA are commercially available: the ELISA-
based QuantiFERONW-TB Gold In-Tube (QFT) and the
ELISPOT-based T-SPOT.TBW. So far, a borderline zone
is recommended for the T-SPOT.TB by the Centers for
Disease Control and Prevention (CDC) as well as the
European Centers for Disease Control and Prevention
(ECDC) [14,15]. However, this recommendation is based
on two rather small studies [16,17] and so far no con-
sensus has been reached regarding the definition of such
a borderline zone for the QFT.
Therefore, we reanalysed our data concerning TB and
progression towards active TB in HCW screened with the
QFT [18], using a borderline zone from 0.2 to <0.7 IU/mL
for the specific INF-γ release.
Methods
All workers at the Hospital São João are offered TB
screening according to guidelines from the CDC [1].
Upon starting employment, all workers are examined toTable 1 Results of IGRA and TB in HCW
TB QFT r
Negative Borde
<0.2 IU/mL 0.2– <0.
n % N
TB in history 16 28.1 15
Active TB at screening 0 - 2
Progression to active TB 0 - 1
No TB 1,764 62.7 323
All 1,780 61.7 341exclude active TB and to assess their pre-employment
status. Depending on the risk assessment, the examin-
ation is repeated annually or every other year. HCW
with close contact to patients in the infection and TB
wards are considered to be at a high risk, workers with
regular contact to patients in the other wards are con-
sidered to be at a medium risk and workers with no
regular patient contact and no contact with biological
material are considered to be at a low risk. After unpro-
tected contact with an infectious patient, co-worker or
material, screening is performed as well.
Since January 2007, screening has been performed
using the IGRA. A chest X-ray is performed in order to
exclude active pulmonary disease when the IGRA is
positive and in HCW with symptoms. For the IGRA, the
QuantiFERON-TBW Gold In-Tube assay (Cellestis Lim-
ited, Carnegie, Australia) is used. This whole-blood assay
uses overlapping peptides corresponding to ESAT-6,
CFP-10 and a portion of the tuberculosis antigen TB7.7esults Total
rline Positive
7 IU/mL ≥0.7 IU/mL
% n % n %
26.3 26 45.6 57 2.0
25.0 6 75.0 8 0.3
25.0 3 75.0 4 0.1
11.5 728 25.9 2,815 97.6
11.8 763 26.5 2,884 100.0
Table 2 Conversion and reversion rates depending on the use of a borderline zone and the INF-γ concentration of the
first QFT
First QFT Second QFT Total
<0.2 IU/mL 0.2– <0.7 IU/mL ≥0.7 IU/mL
n % n % n % n %
<0.2 IU/mL 588 82.0 73 10.2 56 7.8 717 59.8
0.2– < 0.35 IU/mL 24 35.3 18 26.5 26 38.2 68 5.7
0.35– < 0.7 IU/mL 48 45.7 21 20.0 36 34.3 105 8.8
≥0.7 IU/mL 45 14.6 46 14.9 218 70.6 309 25.8
All 705 58.8 158 13.2 336 28.0 1199 100.0
Table 4 Conversion and reversion rates depending on the
use of a borderline zone and the time span between the










n % n % n % n %
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within the tube used to collect blood. The tubes were
incubated overnight at 37°C before centrifugation, and
INF-γ release is measured by ELISA according to the
manufacturer’s protocol. All assays performed met the
manufacturer’s quality control standards. The test is
considered positive when INF-γ is ≥0.35 IU/mL after
correction for the negative control.
For this analysis, a borderline zone from 0.2 to
<0.7 IU/mL was assumed, as proposed by a multicentre
analysis of serial QFT testing in HCW [19]. Therefore, a
QFT result of <0.2 IU/mL was considered negative, a
result of 0.2 to <0.7 IU/mL was considered borderline
and a result of ≥0.7 IU/mL was considered positive.
Data analysis was performed using SPSS, Version 14
(SPSS Inc., Chicago, Illinois). All persons gave their
informed consent prior to their inclusion in the study. No
additional data was collected for the purposes of the study
and the analysis was performed using anonymous data.
Therefore, no endorsement by an ethics committee was
required.
Results
The study population comprises 2,885 HCW (Figure 1).
The IGRA was indeterminate in five HCW. 61.7% of the
HCW had a QFT result below the borderline zone
(<0.2 IU/mL). 11.8% had a result falling into the borderline
zone and 25.9% of the HCW tested had a positive QFT
(≥0.7 IU/mL). Fifty-seven (2.0%) HCW had a history of ac-
tive TB. Active TB was diagnosed in eight HCW during
screening and four HCW showed progression towardsTable 3 Results of the first and second QFT (negative:





n % n % n %
Negative 657 83.7 128 16.3 785
Positive 120 29.0 294 71.0 414
All 777 64.8 422 35.2 1,199 100.0active TB after a positive IGRA. Out of the 57 HCW with
an active TB in their history, 16 (28.1%) had a negative
IGRA and 15 (26.3%) had an IGRA result that pertains to
the borderline zone (Table 1). None of the HCW with a
negative IGRA result was diagnosed with active TB during
screening, or developed active TB during the follow-up
period. Two HCW out of eight (25%) with active TB at
the time of screening had IGRA results falling into the
borderline zone. One HCW out of four (25%) who pro-
gressed towards active TB after a positive IGRA result in
the screening had an IGRA result that belongs in the
borderline zone. Therefore, applying a borderline zone
would have rendered the diagnosis of TB more difficult in
three (25%) HCW out of twelve in whom active TB was
observed.
A second IGRA was performed in 1,199 HCW. The
average time span between the two IGRA was 13.5 months
(range: 0–44 months, standard deviation: 8.5 months). The
result of the first IGRA was <0.2 IU/mL in 717 (59.8%),
and the result of the second IGRA was <0.2 IU/mL in 705
(58.8%) HCW (Table 2). The number of HCW with a posi-
tive IGRA (≥0.7 IU/mL) increased from 309 (25.7%) in the
first IGRA to 336 (28.0%) in the second IGRA. In total,First QFT <0.2 IU/mL
<9 months 167 83.1 22 10.9 12 6.0 201 100.0
9– < 16 months 263 89.5 19 6.5 12 4.1 294 100.0
≥16 months 158 71.2 32 14.4 32 14.4 222 100.0
First QFT ≥0.7 IU/mL
<9 months 34 30.6 15 13.5 62 55.9 111 100.0
9– < 16 months 4 3.8 16 15.2 85 81.0 105 100.0
≥16 months 7 7.5 15 16.1 71 76.3 93 100.0
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pertaining to the borderline zone (calculated from Table 2).
A conversion defined as trespassing of the borderline zone
from negative to positive was observed in 56 (7.8%) of the
HCW with a negative (<0.2 IU/mL) first IGRA. A reversion
analogous to this definition was observed in 45 (14.6%) of
the HCW with a first IGRA result of ≥0.7 IU/mL. With a
simple dichotomous approach, conversion and reversion
rates were about twice as high at 16.3% and 29.0%, respect-
ively (Table 3).
With the time between the two IGRA the probability of
a conversion (trespassing the borderline zone) increased
(Table 4). However, the increase was not monotonous.
With less than nine months between the two IGRA, the
conversion rate was 6.0%, with nine to 16 months in be-
tween it was 4.1% and with ≥16 months it was 14.4%
(Table 4). The reversion rate did decrease with time from
30.6% to 3.8% and 7.5%, respectively.
Discussion
This is the first study to report data on disease detection
in TB screenings of HCW and on disease prediction with
the IGRA using a borderline zone for the interpretation of
the QFT. Applying a borderline zone, the conversion was
reduced to 7.8%, which seems to be more realistic than
the 14.6% with a dichotomous approach, taking the rela-
tively short average time span between the two IGRA into
consideration (mean: 13.5 months). The reversion rate is
reduced from 29.0% to 14.6%. Assuming that a latent TB
infection (LTBI) is long lasting and immunologic
responses to the LTBI do not change rapidly, the lower re-
version rate might be more realistic, too.
However, introducing a borderline zone comes with a
price. The QFT is less sensitive for active TB and for the
prediction of TB when a borderline zone is applied and a
chest X-ray is not performed in those with a QFT result
within the borderline zone. In our population in particular,
25% of the active TB cases detected would probably have
suffered from delayed diagnosis when strictly applying the
borderline zone. As the positive predictive value of a la-
boratory test increases with the prevalence of the diseases
tested for and vice versa, it might be safe to assume that in
a population with a very low prevalence, and therefore in-
cidence, of active TB, the application of a borderline zone
is beneficial. Under these circumstances, the number of
X-rays and preventive chemotherapies is reduced, render-
ing the screening to likely be more efficient. The HCW
studies from the United States published recently might
describe typical cohorts that will profit from the introduc-
tion of a borderline zone for QFT. In these studies, the
rates of positive QFT were low and reversion rates were
high [20-22]. In parenthesis, it might be considered if TB
screening in these populations is efficient at all. In a popu-
lation with a higher risk of TB, the introduction of aborderline zone for the QFT may be harmful, as was
shown by our data.
To our dismay, we are not able to propose which TB
prevalence the use of a borderline zone for the QFT might
be useful for. Until today, data on disease detection in TB
screenings of HCW and on disease prediction with the
IGRA has been frustratingly sparse or non-existent. For
contact tracings, the situation is much better, as recent
publications from two large studies from Germany and
the UK are available [23-25]. However, these studies did
not consider the use of a borderline zone. In the German
contact tracing study [24], progression to active TB was,
however, observed in close contacts with a positive QFT
result of between 0.35 and 0.7 IU/mL. Therefore, for these
contact tracings, the use of a borderline zone for the QFT
is not advisable, either.
For the T-SPOT.TB, a borderline zone has already
been proposed by the CDC and ECDC [14,15]. How-
ever, as mentioned above, the recommendation is based
on little data. As it was shown that the specificity of the
T-SPOT. TB is lower than the specificity of the QFT
[26], an analogous approach to the QFT might not be
justified.
The use of the IGRA for screening close contacts or
HCW is endorsed in several national guidelines [15,27-29].
Taking the advantages of the IGRA over the tuberculin
skin test into consideration, this is well justified. However,
these guidelines lack the recommendation to systematic-
ally evaluate the screenings in order to better understand
their effectiveness and efficiency and the role of the IGRA
within these endeavours. Before consensus on the use of a
borderline zone for the QFT can be reached, more and
better data on disease prediction with the QFT is needed.
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